**Amgen’s Mixed Trial Results: Rocatinlimab & Uplizna**
Amgen recently released topline Phase III trial data for two of its investigational drugs, rocatinlimab and Uplizna, showing a mix of promising and challenging results that could impact their future in competitive markets.
**Rocatinlimab for Atopic Dermatitis (AD)**
Developed in collaboration with Kyowa Kirin, rocatinlimab is an OX40 inhibitor targeting moderate-to-severe atopic dermatitis. The data revealed that rocatinlimab demonstrated a clinically significant improvement in symptom severity. However, the drug did not meet all primary endpoints, which could affect its future positioning against entrenched competitors like Regeneron’s Dupixent.
**Uplizna for Myasthenia Gravis**
Uplizna, a CD19 inhibitor, was tested on adults with generalized myasthenia gravis, an autoimmune disorder affecting muscle strength. The trial results showed that Uplizna met its primary endpoint, significantly reducing disease exacerbation compared to the placebo. This positive outcome strengthens Uplizna’s potential in expanding its use beyond neuromyelitis optica spectrum disorder, its current approved indication. However, it will still face competition from other therapies, such as argenx’s Vyvgart.
**Strategic Implications for Amgen**
Amgen’s decision to release these topline results is part of a broader strategy that demonstrates